Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash from Operations (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Cash from Operations for 6 consecutive years, with 44865000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 22.47% to 44865000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 235455000.0, a 5.48% increase, with the full-year FY2025 number at 235455000.0, up 5.48% from a year prior.
  • Cash from Operations was 44865000.0 for Q4 2025 at Relay Therapeutics, up from 62119000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 46640000.0 in Q1 2021 to a low of 89188000.0 in Q4 2023.
  • A 5-year average of 54438700.0 and a median of 57480500.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: soared 308.83% in 2021, then crashed 205.43% in 2022.
  • Relay Therapeutics' Cash from Operations stood at 39707000.0 in 2021, then tumbled by 43.75% to 57079000.0 in 2022, then tumbled by 56.25% to 89188000.0 in 2023, then surged by 35.12% to 57868000.0 in 2024, then grew by 22.47% to 44865000.0 in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Cash from Operations are 44865000.0 (Q4 2025), 62119000.0 (Q3 2025), and 55261000.0 (Q2 2025).